Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Treatment of early stage adenocarcinoma

Choosing Wisely: Value added cancer care for India

Published: 20 Feb 2020

Views: 1591

Rating:

Save

Dr C S Pramesh - Tata Memorial Hospital, Mumbai, India

Prof C S Pramesh presents a talk on 'Treatment of early stage adenocarcinoma' at the Choosing wisely: Value Added Cancer Care for India event in New Delhi.

Related Videos

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Time toxicity: the burden on cancer patients

Dr Arjun Gupta - University of Minnesota, Minneapolis, USA

Time toxicity: the burden on cancer patients ( Dr Arjun Gupta - University of Minnesota, Minneapolis, USA )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

VT3989 is safe and well tolerated in patients with advanced malignant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

To avoid unnecessary second surgery in differentiated thyroid cancer

Dr Thou Sarameth - Calmette Hospital, Phnom Penh, Cambodia

To avoid unnecessary second surgery in differentiated thyroid cancer ( Dr Thou Sarameth - Calmette Hospital, Phnom Penh, Cambodia )

More from ecancer

An Error Occurred: Internal Server Error

Oops! An Error Occurred

The server returned a "500 Internal Server Error".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.